The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

13 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Cytosporone B is an agonist for nuclear orphan receptor Nur77.EBI
Xiamen University
Exploring Fatty Acid Mimetics as NR4A Ligands.EBI
Ludwig Maximilian University of Munich
Development of a Potent Nurr1 Agonist Tool for In Vivo Applications.EBI
Ludwig Maximilian University of Munich
Discovery of 5-(Pyrimidin-2-ylamino)-1EBI
Xiamen University
Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77.EBI
Xiamen University
Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation.EBI
Goethe University Frankfurt
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.EBI
The Scripps Research Institute
Optimization of novel oxidative DIMs as Nur77 modulators of the Nur77-Bcl-2 apoptotic pathway.EBI
Xiamen University
Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators.EBI
Xiamen University
SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.EBI
Xiamen University
Protein kinase inhibitor containing pyrrolopyridazine derivativeBDB
The Asan Foundation
Macrocyclic compounds as IRAK1/4 inhibitors and uses thereofBDB
Merck Patent
Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitorsBDB
Hoffmann-La Roche